8-K: Arcadia Biosciences Reports Strong Q3 2024 Results Driven by Zola Coconut Water Growth

Arcadia Biosciences announced an 18% year-over-year increase in total revenue for the third quarter of 2024, fueled by a 55% surge in Zola coconut water sales and a 68% expansion in Zola's retail distribution.

Summary

• Arcadia Biosciences reported its financial results for the third quarter of 2024, showing an 18% increase in total revenue compared to the same period last year, reaching $1.537 million.
• The growth was primarily driven by Zola coconut water, which saw a 55% increase in revenue and a 68% expansion in retail distribution year-over-year.
• The company's operating expenses increased by $602,000 in Q3 2024 compared to Q3 2023, mainly due to higher revenues and employee severance costs.
• However, operating expenses decreased by $3.4 million for the first nine months of 2024 compared to the same period in 2023, due to a $4.0 million gain from an asset sale to Corteva.
• Net loss attributable to common stockholders improved to $1.6 million in Q3 2024, compared to $2.6 million in Q3 2023, and to $3.0 million for the first nine months of 2024, compared to $11.1 million for the same period in 2023.
• The company has significantly reduced its use of operating cash to the lowest levels in its history as a public company.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth, particularly in the Zola brand, and significant improvements in net loss and cash management. The company's management is optimistic, and the results are better than expected. However, there are still some challenges with operating expenses and the company is still reporting a net loss.

Positives

• The company experienced significant revenue growth, driven by the strong performance of Zola coconut water.
• Zola is gaining market share and growing faster than the overall coconut water category.
• Operating cash usage has been significantly reduced.
• The net loss attributable to common stockholders has improved substantially both in the third quarter and for the first nine months of 2024.
• The company realized a $4.0 million gain from an asset sale to Corteva.

Negatives

• Operating expenses increased by $602,000 in the third quarter of 2024 compared to the same period in 2023.
• Selling, general and administrative expenses increased due to employee severance costs and higher consulting and legal expenses.
• The company still reported a net loss attributable to common stockholders of $1.6 million for the third quarter of 2024.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.
• The company's future performance is not guaranteed based on the current results.
• The company's filings with the Securities and Exchange Commission outline additional risks and uncertainties.

Future Outlook

The company's future performance is subject to risks and uncertainties, and reported results should not be considered as an indication of future performance. The company disclaims any obligation to update forward-looking statements.

Management Comments

• T.J. Schaefer, Arcadia's president and CEO, stated that they are extremely pleased with the third-quarter 2024 results, which represent the progress they have made in transforming Arcadia's business.
• Schaefer also noted that the company has significantly reduced its use of operating cash to the lowest levels in Arcadia's history as a public company.
• Schaefer mentioned that Zola is gaining market share and growing faster than the coconut water category across all measured time periods.

Industry Context

The announcement reflects a positive trend in the plant-based health and wellness sector, with Arcadia's Zola brand showing strong growth in the competitive coconut water market. This performance suggests that the company's focus on innovative, plant-based products is resonating with consumers.

Comparison to Industry Standards

• While specific competitor data is not provided, the 55% growth in Zola coconut water revenue and 68% expansion in retail distribution significantly outpaces the overall coconut water category growth, suggesting a strong competitive position.
• Companies like Vita Coco and other major beverage brands are key competitors in the coconut water space, and Arcadia's growth indicates a successful strategy in gaining market share.
• The reduction in operating cash usage is a positive sign, as many companies in the early stages of growth often struggle with cash flow management.

Stakeholder Impact

• Shareholders will likely view the strong revenue growth and improved net loss positively.
• Employees may be impacted by the severance costs mentioned in the report.
• Customers of Zola coconut water will benefit from the increased availability of the product.
• Suppliers may see increased demand due to the growth of the Zola brand.

Next Steps

• The company has scheduled a conference call to discuss the third-quarter results and key strategic achievements.
• A recorded replay of the conference call will be available on the company's website.

Key Dates

Keywords

Arcadia Biosciences, Zola coconut water, financial results, revenue growth, operating expenses, net loss, retail distribution, plant-based products, health and wellness